Breathe Well Live Well
|
Experimental Drug May Cut Severe Asthma Attacks: Study
iVillage Entertainment THURSDAY, Aug. 16 (HealthDay News) — An experimental drug known as mepolizumab may reduce outbreaks by almost 50 percent in people with a type of hard-to-treat asthma, an early study finds. About a third of people with severe asthma have what is … |
View full post on asthma – Google News
|
GSK runs to PhIII with upbeat data on drug for severe asthma
FierceBiotech GlaxoSmithKline ($GSK) generated positive results from a mid-stage trial for its experimental drug in patients with an uncommon form of asthma, giving the London drug giant confidence in advancing the program to Phase III development before the end of … |
View full post on asthma – Google News
 Telegraph.co.uk |
Glaxo's Experimental Drug Halves Asthma Attacks in Study
Businessweek Among 621 participants with severe asthma, after a year of treatment, the rate of attacks requiring oral corticosteroids, emergency room visits or hospitalizations was about half for those taking one of three monthly doses of the drug, called … Experimental Drug May Cut Severe Asthma Attacks: Study GSK drug halves attacks in hard-to-treat asthma Experimental drug halves attacks in hard-to-treat asthma |
View full post on asthma – Google News
Telegraph.co.uk |
GlaxoSmithKline asthma drug cuts number of attacks
Telegraph.co.uk He said: “It seems to be a safe and effective treatment option for patients with eosinophilic asthma that is associated with frequent flare-ups, and may reduce the need for conventional treatment with oral corticosteroids that can have serious side … |
View full post on asthma – Google News
 Telegraph.co.uk |
Experimental Drug May Cut Severe Asthma Attacks: Study
U.S. News & World Report About a third of people with severe asthma have what is called eosinophilic asthma, in which inflammatory cells called eosinophils cause swelling of lung airways. Standard asthma treatment with inhaled steroids isn't effective, so these patients take … Experimental drug halves attacks in hard-to-treat asthma GSK drug halves attacks in hard-to-treat asthma GSK runs to Ph3 with upbeat data on drug for severe asthma |
View full post on asthma – Google News
Telegraph.co.uk |
Experimental Drug May Cut Severe Asthma Attacks: Study
Philadelphia Inquirer About a third of people with severe asthma have what is called eosinophilic asthma, in which inflammatory cells called eosinophils cause swelling of lung airways. Standard asthma treatment with inhaled steroids isn't effective, so these patients take … Experimental drug halves attacks in hard-to-treat asthma GSK drug halves attacks in hard-to-treat asthma GSK runs to Ph3 with upbeat data on drug for severe asthma |
View full post on asthma – Google News
Telegraph.co.uk |
Experimental drug halves attacks in hard-to-treat asthma
Fox News The injectable antibody treatment mepolizumab is designed to help a small group of people with asthma in which white blood cells called eosinophils cause inflammation of lung airways. It reduces the number of eosinophils by inhibiting an immune system … GSK drug halves attacks in hard-to-treat asthma GSK runs to Ph3 with upbeat data on drug for severe asthma Experimental Drug May Cut Severe Asthma Attacks: Study |
View full post on asthma – Google News
|
New drug 'stops common cold asthma deaths'
Todmorden Today The news is based solely on a press release, which gives some information about the findings of an early-stage clinical trial of a new, unlicensed asthma drug called SNG001. The press release describes research that was conducted in a total of 134 … |
View full post on asthma – Google News
|
GSK drug halves attacks in hard-to-treat asthma
Chicago Tribune LONDON (Reuters) – An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success … |
View full post on asthma – Google News
|
GSK drug halves attacks in hard-to-treat asthma
Reuters LONDON (Reuters) – An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success … GlaxoSmithKline Sees Promise in New Drug for Severe Asthma |
View full post on asthma – Google News